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Letter: The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical 
trials and longitudinal observational studies 
Reply to: How are enthesitis, dactylitis and nail involvement measured and reported in recent 
clinical trials of psoriatic arthritis? A systematic literature review 
 
Dear Sir, 
We read with interest the recent letter by Ramiro et al reporting data from a systematic 
literature review on the measurement of enthesitis, dactylitis and nail disease in Psoriatic 
Arthritis (PsA) clinical trials. The authors highlight the great variety in the outcome measures 
chosen, cut points and the statistical analysis performed (percentage change, proportion 
resolved).  We are pleased the authors have highlighted this problem and agree with their 
viewpoints on the clear lack of standardisation of domains and instruments in clinical trials 
evidenced by the data.  Indeed this inconsistency of data reporting has led to significant 
heterogeneity in both physician assessed and patient reported outcomes particularly in the 
field of PsA.  It is the domains of enthesitis, dactylitis, nail disease as well as skin and axial 
disease, and the unique impact they subsequently have on physical function and quality of life 
for patients with PsA, that differentiate psoriatic arthritis from other types of inflammatory 
arthritis like rheumatoid arthritis (RA). Therefore the accurate assessments of these disease 
manifestations are of vital importance in drug trials.    
In an effort to standardise outcome assessment in PsA the first PsA core domain set to be was 
developed in 2006 by the Group for Research and Assessment of Psoriasis and Psoriatic 
Arthritis (GRAPPA) Outcome Measures in Rheumatology (OMERACT) working group.[1] This 
PsA core domain set represented the minimum set of outcomes to be measured in 
randomized controlled trials (RCTs) and longitudinal observational studies (LOS). A systematic 
literature review demonstrated increased measurement of the complete PsA core domain set 
from 23.5% of RCT’s in 2006-2010 to 59% of RCTs in 2010–2015. [2] The PsA core domain set 
was updated, with enhanced patient representation, in 2016 following an extensive program 
of work.[3]  As Ramiro et al state the next step is to generate instruments and cut offs for the 
measurement of these domains; a Core Outcome Measurement Set.  
Several international work streams comprise the Core Outcome Measures for Psoriatic 
Arthritis Clinical Trials (COMPACT) study and have been underway since 2016 to address 
specifically this problem. The GRAPPA-OMERACT PsA Core Set working group is leading this 
work following OMERACT Filter 2.0 methodology.[4]  This program of work includes multiple 
systematic literature reviews, incorporating data up to 2017, in order to synthesise the 
existing evidence on PsA instrument properties (across RCT and LOS data sources as the 
authors suggest), a Delphi process with stakeholders (including patients, clinicians, trialists, 
methodologists and payers), working group meetings and discussion and voting at OMERACT 
2018. The resulting Core Outcome Measurement Set will synthesise the evidence and provide 
guidance for the use of PsA outcome instruments, including not only enthesitis, dactylitis and 
nail involvement, as discussed by Ramiro et al, but all pathophysiological manifestations, life 
impact and resource use defined in the PsA core domain set.  
The OMERACT[5] and Core Outcomes Measurement for Effectiveness Trials (COMET) 
methodology[6] we are following in the COMPACT study will provide evidence based guidance 
with international consensus on the best instruments to measure the domains of psoriatic 
disease and, equally importantly identify current gaps and a research agenda to generate the 
evidence.  In the near future, this will facilitate standardisation of outcomes chosen in clinical 
trials whilst ensuring that key domains important to both patients and physicians are assessed. 
The report by Ramiro et al highlights the importance of developing a framework of domains 
and valid instruments for the consistent assessment of Psoriatic Arthritis in RCT’s and 
observational studies and we suggest herein a robust framework, underway, to achieve this 
standardisation. 
 
William Tillett 
Ana-Maria Orbai,  
Alexis Ogdie,  
Ying Ying Leung, 
Vibeke Strand,  
Dafna Gladman, 
Philip Mease,  
Laura Coates, 
On Behalf of the GRAPPA OMERACT Psoriatic Arthritis working group.  
 References 
1. Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, et al. Consensus 
on a core set of domains for psoriatic arthritis. J Rheumatol. 2007 May; 34(5):1167-1170. 
2. Kalyoncu U, Ogdie A, Campbell W, Bingham CO, 3rd, de Wit M, Gladman DD, et al. 
Systematic literature review of domains assessed in psoriatic arthritis to inform the update 
of the psoriatic arthritis core domain set. RMD open. 2016; 2(1):e000217. 
3. Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, et al. International 
patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. 
Ann Rheum Dis. 2016 Apr; 76(4):673-680. 
4. Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d'Agostino MA, et al. Developing 
core outcome measurement sets for clinical trials: OMERACT filter 2.0. Journal of clinical 
epidemiology. 2014 Jul; 67(7):745-753. 
5. Tugwell P, Boers M, D'Agostino MA, Beaton D, Boonen A, Bingham CO, 3rd, et al. 
Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments 
through assessment of "truth": content, face, and construct validity. J Rheumatol. 2014 May; 
41(5):1000-1004. 
6. Prinsen CA, Vohra S, Rose MR, King-Jones S, Ishaque S, Bhaloo Z, et al. Core 
Outcome Measures in Effectiveness Trials (COMET) initiative: protocol for an international 
Delphi study to achieve consensus on how to select outcome measurement instruments for 
outcomes included in a 'core outcome set'. Trials. 2014 Jun 25; 15:247. 
 
